These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38479497)

  • 81. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.
    Dobarro D; Donoso-Trenado V; Solé-González E; Moliner-Abós C; Garcia-Pinilla JM; Lopez-Fernandez S; Ruiz-Bustillo S; Diez-Lopez C; Castrodeza J; Méndez-Fernández AB; Vaqueriza-Cubillo D; Cobo-Marcos M; Tobar J; Sagasti-Aboitiz I; Rodriguez M; Escolar V; Abecia A; Codina P; Gómez-Otero I; Pastor F; Marzoa-Rivas R; González-Babarro E; de Juan-Baguda J; Melendo-Viu M; de Frutos F; Gonzalez-Costello J
    ESC Heart Fail; 2023 Apr; 10(2):1193-1204. PubMed ID: 36655614
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
    Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
    Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
    Ibrahim NE; Gaggin HK; Rabideau DJ; Gandhi PU; Mallick A; Januzzi JL
    J Card Fail; 2017 Feb; 23(2):121-130. PubMed ID: 27469482
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
    Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
    J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Inotropic and lusitropic effects of levosimendan and milrinone assessed by strain echocardiography-A randomised trial.
    Fredholm M; Jörgensen K; Houltz E; Ricksten SE
    Acta Anaesthesiol Scand; 2018 Oct; 62(9):1246-1254. PubMed ID: 29926912
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.
    Papp Z; Agostoni P; Alvarez J; Bettex D; Bouchez S; Brito D; Černý V; Comin-Colet J; Crespo-Leiro MG; Delgado JF; Édes I; Eremenko AA; Farmakis D; Fedele F; Fonseca C; Fruhwald S; Girardis M; Guarracino F; Harjola VP; Heringlake M; Herpain A; Heunks LMA; Husebye T; Ivancan V; Karason K; Kaul S; Kivikko M; Kubica J; Masip J; Matskeplishvili S; Mebazaa A; Nieminen MS; Oliva F; Papp JG; Parissis J; Parkhomenko A; Põder P; Pölzl G; Reinecke A; Ricksten SE; Riha H; Rudiger A; Sarapohja T; Schwinger RHG; Toller W; Tritapepe L; Tschöpe C; Wikström G; Lewinski DV; Vrtovec B; Pollesello P
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):4-22. PubMed ID: 32639325
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy.
    Sumanaru D; Josseran L; Essid A; Mbieleu B; Haegy I; Bergounioux J
    Pediatr Cardiol; 2019 Mar; 40(3):668-670. PubMed ID: 30796500
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure.
    Lunghetti S; Palmerini E; Urselli R; Maffei S; Guarino E; Focardi M; Mondillo S; Favilli R
    Cardiol J; 2011; 18(5):532-7. PubMed ID: 21947989
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.
    Hummel J; Rücker G; Stiller B
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011312. PubMed ID: 28262914
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.
    Hummel J; Rücker G; Stiller B
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011312. PubMed ID: 28770972
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
    Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
    JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
    Berg DD; Samsky MD; Velazquez EJ; Duffy CI; Gurmu Y; Braunwald E; Morrow DA; DeVore AD
    Circ Heart Fail; 2021 Feb; 14(2):e007034. PubMed ID: 33530704
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Influence of levosimendan on organ dysfunction in patients with severely reduced left ventricular function undergoing cardiac surgery.
    Erb J; Beutlhauser T; Feldheiser A; Schuster B; Treskatsch S; Grubitzsch H; Spies C
    J Int Med Res; 2014 Jun; 42(3):750-64. PubMed ID: 24781725
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [TBL] [Abstract][Full Text] [Related]  

  • 98. [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
    Prijić S; Rakić S; Nikolić L; Jovicić B; Stajević M; Vukomanović V; Kosutić J
    Vojnosanit Pregl; 2011 Nov; 68(11):979-84. PubMed ID: 22191317
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Evaluation of the clinical, hemodynamic and neurohormonal response to levosimendan administration in decompensated heart failure patients. One-month follow-up.
    Sargento L; Brito D; Matias JS; Madeira H
    Rev Port Cardiol; 2007; 26(7-8):717-26. PubMed ID: 17939581
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Levosimendan use in patients with preoperative low ejection fraction undergoing cardiac surgery: A systematic review with meta-analysis and trial sequential analysis.
    Ng KT; Chan XL; Tan W; Wang CY
    J Clin Anesth; 2019 Feb; 52():37-47. PubMed ID: 30172838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.